|Quantity Discounts||1 - 9999|
|1 - 9999|
|1 - 9999|
Just recently, Labopharm appealed an approvable letter for a drug, claiming that the FDA had previously requested additional data analysis that proved its effectiveness and met approval conditions. An expected action date has been set for Jan. 2, 2009.
TMJ Implants, in another instance, objected to an inspection that resulted in a Form 483 and later a warning letter that cited failure to file 17 adverse event reports under MDR regulations. TMJ claimed the events were not reportable under MDR. TMJ won the right to appeal, although they lost the case.
In both instances these companies knew how to properly maneuver through the dispute resolution process.
Knowing when to confront an FDA action and how to take the proper steps towards filing for a request to challenge that action can determine whether or not a review will even be granted.
As companies contend with complete response letters and and an increase in FDA crackdowns on facility inspections, there will be more challenges to negative FDA actions — meaning it’s more important than ever to gain a complete understanding of the dispute resolution process.
In a 90-minute Encore presentation, regulatory expert Steven Hoff will walk you through the formal and informal processes to request a review. He’ll explain whether or not you should make a request. And he’ll follow-up with lessons learned through case studies on firms that have both succeeded and failed.
Sign up your entire team to listen in and discover:
Register now and gain a thorough understanding of how and when to use the FDA’s dispute resolution process. Avoid having your request rejected — take advantage of the processes available to you to get your case in front of the FDA. Plus, you’ll get an opportunity to ask your toughest questions during the Q&A session.
Steven Hoff has worked in biomedical research for more than 30 years, including 17 years of experience in regulatory affairs. He has been involved in numerous INDs, NDAs and supplemental NDAs, along with 510(k)s for devices. Steven has coordinated major meetings and teleconferences with the FDA, prepared the associated briefing documents and performed due diligence efforts. His background includes 12 years of academic research in the areas of cell biology, neuroscience, pharmacology and oncology, along with 25 years teaching medical pharmacology. Steven has served on the faculty for Regulatory Master’s Degree at Purdue University, School of Pharmacy; as co-editor for the RAPS Fundamentals of U.S. Regulatory Affairs in 2003 and 2005; and on the editorial board of the Drug Information Association Journal from 2006 to present.
|Date:||Nov. 17 – Dec. 5, 2008|
|Location:||Your office or conference room (no need to travel!)|
Gather your team for maximum benefit! Your investment is for one dial-in.
We accept American Express, Visa and MasterCard. Make checks payable to FDAnews.
Or, register by phone: toll free (888) 838-5578 (inside the U.S.) or +1 (703) 538-7600
Registrations may not be cancelled. Please contact customer service to make any substitutions.
Copyright ©2018. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing